Compare Becton Dickinson and Co (BDX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Visa Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Visa Inc trades at $355.56 (market cap $677.06B). The key difference: Visa Inc is far larger — about 16.3× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | V | |
|---|---|---|
Market Cap | $41.51B | $677.06B |
Sector | Health | Financials |
52-Week High | $185.39 | $362.13 |
52-Week Low | $135.49 | $295.52 |
Enterprise Value | $57.97B | $687.65B |
Dividend Yield | 2.79% | 0.75% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Visa (V) trades at $357.75, up 2.52% today, with a bullish technical signal and strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue grew to $40.0 billion in 2025, and net income margin remains robust at 51.68%. The stock is near its pivot point of $357, with support at $354 and resistance at $360. Analysts maintain a strong buy consensus, with an average price target of $394.50.
The outlook for Visa is positive, driven by earnings momentum and strategic initiatives like AI-powered commerce tools. However, risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional holdings increasing, the stock offers growth potential but requires monitoring of payment industry disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
